Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
FAQs
Advertise
UsernamePublicRestriction
Tags:
BioPharmaceutical Coronavirus COVID-19 FDA

Most Pharmacies Express Readiness To Administer COVID-19 Vaccines Once Available

Pharmacy Industry Signals Confidence

  • News

Executive Summary

Results of a forthcoming APhA survey show more than one-third of pharmacies are fully prepared to administer the vaccines once they are available, with more still preparing.


You may also be interested in...



Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

Pfizer And Moderna’s Cold War On COVID Gets Competitive

Ahead of anticipated emergency use approvals, Pfizer and Moderna are promoting the benefits of their rival mRNA vaccines.

Bluebird Spins Off Oncology Business As Cell, Gene Therapy Segments Grow Apart

Nick Leschly will become CEO of oncology-focused spinoff, while Andrew Obenshain will help gene therapy-focused bluebird

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical Coronavirus COVID-19 FDA
UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By